Noveko International Inc. Announces $20 million Private Placement



    MONTREAL, April 25 /CNW Telbec/ - Noveko International Inc. (Symbol: EKO
- TSX Venture Exchange) ("Noveko" or "the Company") is pleased to announce
that it has entered into an agreement with a syndicate led by Desjardins
Securities Inc. and including Blackmont Capital Inc. to raise up to a maximum
of $20 million of Units (the "Units") by way of a best efforts private
placement ("the Offering"). Each Unit will consist of one common share of
Noveko and one-half of one common share purchase warrant (the "Warrant"). Each
warrant will entitle the holder to purchase one common share for a period of
24 months following closing of the Offering. The Units will be offered to
accredited investors in the Provinces of Quebec, Ontario, Alberta, and British
Columbia and in other jurisdictions pursuant to applicable private placement
exemptions.
    The securities issued pursuant to the Offering will be subject to a
4 month hold period and the Offering will be subject to normal regulatory
approvals.
    The Company will pay a 7% cash commission (3.5% on the President's List)
to the Agents and issue to the Agents warrants (the "Broker Warrants")
entitling them to purchase that number of common shares of the Company as is
equal to 7% of the number of Units sold under the Offering.
    The securities offered have not been registered under the U.S. Securities
Act of 1933, as amended, and may not be offered or sold in the United States
absent registration or an applicable exemption from the registration
requirements. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of the securities
in any State in which such offer, solicitation or sale would be unlawful.
    The net proceeds of the offering will be used for the marketing of
derivative products from its patented antimicrobial filtration technology
(antimicrobial masks and antimicrobial air filters), new product development
and general corporate purposes.
    Over the past 12 months, Noveko has initiated major developments in two
of its business sectors, specifically the biomedical and environmental fields.
With its patented antimicrobial filtration technology, it has started to
market two broad lines of derivative products: - antimicrobial masks targeted
to the healthcare sector, pharmaceutical companies and the general public -
and antimicrobial air filters for healthcare institutions, commercial
buildings, residential properties and farm buildings.
    To that end, Noveko has entered into alliances with North American and
Asian supplier-partners and distributors for the manufacture and marketing of
antimicrobial masks. Moreover, the Company recently signed an exclusive
distribution agreement with Monitrol Inc., a North American leader in
ventilation management software and hardware for farm buildings, under which
Monitrol will distribute its antimicrobial air filters in the hog and poultry
breeding markets in North America.
    Noveko is currently completing the tests required to obtain 510K
certification for the derivative products from its antimicrobial technology
and expects to obtain FDA approval by late summer 2007.
    The Company intends to use the proceeds from the private placement to
primarily step up the marketing of antimicrobial masks and air filters in
different countries - a market with considerable potential in North America
and worldwide. It also plans to develop other derivative products from its
patented antimicrobial technology and to accelerate the development of new
technological platforms in the field of real-time portable ultrasound scanners
for veterinary and human medicine.

    Profile
    -------

    Noveko International Inc. currently has three subsidiaries: S.A.S. ECM
(France), Noveko Inc. and Bolduc Leroux Inc. (BLI). ECM specializes in the
design and marketing of portable real-time ultrasound scanners for use in
veterinary and human medicine. Noveko Inc. develops the Company's biomedical
and environmental business, specifically its patented antimicrobial filtration
technology and derivative products (antimicrobial face masks and filters). For
its part, BLI specializes in the custom processing and distribution of steel
products based on client specifications and designs. It has also developed and
markets a line of downdraft particle extraction tables for various industrial,
commercial and pharmaceutical markets. Operating since September 2002, the
Company was listed on the TSX Venture Exchange on February 3, 2004.

    The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.




For further information:

For further information: André Leroux, Chairman of the Board and Chief
Executive Officer, Noveko International Inc., (514) 344-3030; Alain Bolduc,
President and Chief Operating Officer, Noveko International Inc., (514)
344-3030; http://www.noveko.com/

Organization Profile

Noveko International Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890